U.S., April 8 -- ClinicalTrials.gov registry received information related to the study (NCT07515924) titled 'Oral Gallium Maltolate for Recurrent Glioblastoma' on March 31.
Brief Summary: This is a Phase 0 investigational study to assess the central nervous system penetration and tumoral concentration of gallium in patients with recurrent glioblastoma administered with preoperative gallium maltolate.
Study Start Date: June, 2026
Study Type: INTERVENTIONAL
Condition:
Glioblastoma
Intervention:
DRUG: Gallium Maltolate
Gallium Maltolate will be administered at a total daily dose of 2500 mg.
PROCEDURE: Surgical Intervention
Patients will be scheduled for surgical intervention (needle biopsy or resection) as deemed necessary by the cli...